The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors
- 1 July 2007
- journal article
- case report
- Published by Elsevier BV in The Journal of the American Dental Association
- Vol. 138 (7), 971-977
- https://doi.org/10.14219/jada.archive.2007.0294
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Discovery, Clinical Development, and Therapeutic Uses of BisphosphonatesAnnals of Pharmacotherapy, 2005
- Long-Term Safety of BisphosphonatesJournal of Clinical Endocrinology & Metabolism, 2005
- Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 casesJournal of Oral Pathology & Medicine, 2005
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJournal of Oral and Maxillofacial Surgery, 2004
- Platelet-rich plasma: evidence to support its useJournal of Oral and Maxillofacial Surgery, 2004
- Bisphosphonates and bone necrosis.Journal of Oral and Maxillofacial Surgery, 2004
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regenerationInternational Journal of Oral & Maxillofacial Surgery, 2002
- Platelet-rich plasmaOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 1998